Hi all
pretty new to all this. I have pumped some into Deltex - looks like a strong product with good growth. Could be a steady gainer.
Does anyone else have this, and anyone have some research on it? Someone with more experience than me!
thanks in advance.
Grajul

THE COUNT--->ALL

Below is the history for achieving the first million pounds worth of sales for UK only.

In 2003, the 1st million sales was achieved by 20th Nov.

In 2004, the 1st million sales was achieved by 15th Sep.

In 2005, the 1st million sales was achieved by 27th July.

In 2006, the 1st million sales was achieved by 21st June.

In 2007, the 1st million sales was achieved by 31st May.

In 2008, the 1st million sales was achieved by 25th April.


The slow and steady track of growth is intact. We only need one of the many intiatives being pursued at the moment to kick off and then things should really start to get interesting.

Regards,

THE COUNT!

Interesting (positive) figures.

So NICE are to cut the time of drug approval from 2 years to 6 months. NICE have been taking those 2 years to decide if a drug should be generally available on the NHS, and this is after the drug has been through all the safety approval trials which NICE already except. It has also been mentioned that patient may have a right to these drugs once given Nice approval, and yet differing NHS trusts still often make their own decision as to having that particular drug available.
Although it has been proven AND excepted by all the relevant authorities that the CardioQ saves lives and money (a no brainer), the NHS still don't have orders in for as many as could be needed, so the chances of any organization connected with the NHS, or the government deciding anything within a 6 month time frame is not credible.
Anything this government releases re the NHS, is just more spin.
Still a great believer in he Cardio, and as confident as ever we will get there, but the main route will not be via the NHS.
I would love to be proven wrong.

Latest trial results.
They indicate results consistent with previous trials in other types of surgery including reduced post-operative complications and reduced lengths of hospital stay.
The full study is designed to include over 100 patients and the doctors expect it to take at least another 18 months to complete, although further interim results may become available sooner.

Also.
Three non-executive directors have elected to take shares in lieu of a cash payment as remuneration for their services to the Company. In addition, certain of the Company's advisor's have elected to take shares in lieu of cash payment for their services to the Company.
Always good to see confidence by those in the know.

Like most (almost all) releases by Deltex, it's very positive.

Perhaps Deltex should make a few waves in the media via 3rd parties (just like the government does, but they are called leaks).
Whenever I have explained with friends/colleagues how the CardioQ system works saving lives and money, the usual first response is something like, 'If it's that good, why are the NHS not using it in every hospital'. They like all of us can't see the logic of none general use. If the CardioQ was a drug that saved lives and money, and had passed all the relevant trials that the Cardio has there would be very adverse government aimed comments if they withheld it due to finance.
To me it's nothing short of a scandal.
Although yesterdays news was similar to the many released after trials, there is nothing in the media this morning.
If the CardioQ had been a mega global medical company's product it would have been the subject of mass media interest by now, perhaps even becoming a subject of media debate with our Secretary of State for Health, Alan Johnson.
I would love to see such a debate on TV, with the Secretary desperately trying to find just one reason why such a piece of equipment is not in general use. I think even using pure government speak, he would find it impossible to defend the none general use.
I have never had a share try my patience for so long, but still confident that it will come good, as long as the procrastination of time doesn't overtake the issue.

Nice trading update this morning with the main point being.
The Company expects sales for the six months ended 30 June 2008 to be in excess of 2.4 million and to be more than 25% higher than in the corresponding period in 2007 when sales were 1.9 million.

Comparing sales each quarter to the corresponding quarter in the preceding year, the Company has achieved 10 consecutive quarters of growth in global probe sales, underpinned by 14 consecutive quarters of growth in UK probe sales and eight in International probe sales. Quarterly group probe sales were over 1 million for the first time ever in the second quarter of 2008.

Probably under the present climate, won't make much difference to the sp, but we are slowly heading toward that final fence, IE General UK take up, mass USA/rest of world contacts.
It is only main market sentiment holding this back.

Yes good update gm, encouraging re California and also France, just a matter of time.
2517

Can't remember the last time there were No Trades in Deltex for a complete trading day.

On a day when just about all the market is down Deltex are up 50p on low volume, with sells 2 to 1 against buys.
Probably nothing but it does make one wonder.
Hopefully the several weeks of silence is coming to an end, or am I seeing only what I want to see.

Every little helps.

First Round of Companies to Present at AdvaMed 2008 Selected.

Companies selected to make 14-minute presentations at AdvaMed 2008
include:Deltex.
Designed by industry for industry, AdvaMed 2008 is the premier MedTech
conference for business executives, policymakers, media, financiers, and
service providers from around the world. In its inaugural year, AdvaMed
2007 attracted more than 400 organizations and 1,100 industry leaders -
including 300+ CEOs, Presidents and C-level executives.

http://www.emediaworld.com/press_release/release_detail.php?id=115287

After a quiet few weeks/months nice to see another teaching hospital joining the testing group.
The NHS National Technology Adoption Hub ('NTAH') programme. The Manchester Royal Infirmary ('MRI') is one of the three hospitals enrolled in the NATH programme and Deltex Medical today announces that MRI has purchased four CardioQ-ODM monitors to enable it to participate in the NTAH project.

Not yet the big breakthruogh webreakthrough are all waiting for but I don't mind too much as DEMG are moving further forward with each such move as todays announcement.

From The Daily Telegraph, today.

It appears that the NHS is expected to have a 1.75 billion surplus in the bank by the end of this financial year (as thats about 7 months away I'm not sure how they can say this, but still). Also the figures show that there was a surplus of 1.6 billion at the end of the financial year in April.
What a B****Y scandal.
If these figures are true, just think that this could easily pay for the CardioQ to be used in every NHS hospital in the country with plenty of cash left over.
Obviously there are many other good uses this could be put to, but I can't think of many such ways where the pay back would be in many multiples of cash spent.
We all including the NHS except that money spent on the CardioQ reaps benefits of monetary value and the obvious life saving reasons.
So if true re the surplus yet another no brainer for those great minds of the NHS management to get to grips with. Don't hold your breath for a quick decision though.

Good opportunity for Deltex,

US health technology assessment finds no benefit from pulmonary artery catheters

This represents a tremendous market opportunity for Deltex. All clinical trials on ODM have shown benefit. ODM has never caused a patient an adverse event and, as previously announced, ODM was the subject of a highly positive health technology assessment in 2007 which was also commissioned by CMS. The number of patients for whom CMS deemed ODM both reasonable and necessary is estimated to be at least two or three times higher than even the highest estimate of US PAC use.

On the whole very good. Sales up in most areas, losses down.
Still jam tomorrow but at least we are getting a little taster.
As most on here have said, it's sales that matter and I feel that the next 12 months could be make or break for Deltex.
There are many areas that are still pushing at a stiff door but at least these doors are opening abet slowly.
Slow process still but the feeling is there that things are speeding up.
Still feel that once the ball really starts to roll, it will take some stopping, but as said my personal take is that the next 12 months will be fairly critical for Deltex.

Just back from hols and seen the following RNS from 01/10.08.

Nearly 1,000 colorectal surgeons attending the annual meeting of the European Society of Coloproctology in Nantes, France from 24 to 27 September 2008 heard doctors from Darent Valley Hospital in Kent, England present the outcomes of patients undergoing keyhole bowel surgery over a five year period.

The results covered 238 patients over five years of whom 144 had a CardioQ-ODM and 94 did not. The CardioQ-ODM group of patients was found to have been generally sicker and higher risk prior to surgery yet still did better on the following bases than those fitter, lower risk patients denied the CardioQ-ODM:

Lower hospital stay (7 days vs 9)
Lower mortality (1 patient vs 3)
Lower major complications (6 vs 31)
Lower total complications (20 vs 43)
Lower operative time (162 minutes vs 180)

And yet still the sp is dragged down by this topsey turvy non sensical market.
If Deltex found the secret of internal life the bl**dy sp would drop.

No news out and yet sp down 20%. This is scary.

CardioQ-ODM reduces lengths of stay in Spain by six days.

Dr Ramirez, the lead colorectal surgeon from Hospital General Universitario Zaragoza, reported that the average (mean) length of stay had been reduced by six days per patient. After the introduction of CardioQ-ODM as part on an enhanced recovery protocol, patients were discharged after six days, whereas previously they had stayed in hospital for twelve days. A draft health technology assessment by this Agency, based on results from UK randomised controlled trials, indicated that using the CardioQ-ODM would save 900 per patient, reduce mortality rates and significantly reduce complications: the draft conclusions, although contingent on outcomes from the above audit, were already assessed as 'robust'.

So hospital stays reduced by 50% with the huge monetary saving that that entails, this is yet another NO BRAINER. What the hell is stopping this share zooming upwards like a Nov 5th rocket, instead of dropping like a damp squib.

Looks like I'm talking to myself here.
Getting lonely. Anyone out there or am I the only Deltex shareholder left on MoneyAm.

I'm still in this one greekman, haven't posted for a while because it's the same 'ol same 'ol, every trial has shown the massive benefits of DEMG's products. Sales will be the catalyst for the sp, and I have no doubt over the coming months/years this will be a huge success, as with most aim co's, we just need patience.
2517

Hi George,

Thought you might still be about. Agree it's more of the same.
Never needed so much patience with a share. As you rightly say, sales are all that really matter (catalyst for the sp).

Cheers Greek.

Invitation to visit Chichester facility: Tuesday 25 November 2008

Unable to attend myself, but no doubt someone on here will attend and we will see some feedback in a few weeks.